From $0 to $27.8 Billion | Improving Lives through Rare Disease Treatment |EP62

From a small startup to a global organization, dedicated to treating rare inflammatory autoimmune diseases.

This week we speak to Dr. Jeff Sherman, the Chief Medical Officer at Horizon Therapeutics, a leading biopharmaceutical company that has recently been acquired by Amgen for approximately $27.8 billion.

Dr. Sherman highlights the significance of addressing unmet medical needs and discusses the company's commitment to patients, communities, and healthcare providers. He also reflects on the impact of COVID-19 on their operations and the importance of a sense of urgency in the field of rare diseases.

In the quickfire questions section, Dr. Sherman offers advice to his younger self, outlines the qualities he values most in team members, and emphasizes the value of treating others as you would want to be treated. He also shares his perspective on work-life balance and the joys of being a grandparent.

For more information about Horizon Therapeutics and their work in rare diseases, visit their website at horizontherapeutics.com.